Ironwood Pharmaceuticals Inc. (IRWD) saw its stock surge 28.5% in pre-market trading on Friday, driven by the company's optimistic financial projections for 2026. The biopharmaceutical firm announced that it expects revenue to range between $450 million and $475 million next year, significantly surpassing analyst estimates of $319.4 million.

The company also projected adjusted EBITDA to exceed $300 million in 2026, reflecting disciplined expense management and the positive impact of strategic initiatives. Key to this growth is the anticipated increase in U.S. net sales of its constipation drug, Linzess, which is forecasted to generate between $1.125 billion and $1.175 billion in revenue, driven by improved pricing and demand growth.

Ironwood maintained its 2025 guidance, reinforcing investor confidence in its near-term performance. The strong outlook for 2026 has sparked a rally in the stock, which had previously declined over 20% in the past year.